Find Clinical Trials & Studies

Visit the Research & Education Institute

ARX517/JNJ-95298177 as Monotherapy or Combo Therapy in Metastatic Prostate Cancer (ARX517)

I'm Interested!

Please call
1-800-641-2422

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer

Sex: Male
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Prostate

Study Purpose

This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).

Principal Investigator
Pedro Barata MD

Department/Division
Cancer (Genitourinary)

UH IRB: STUDY20250233
StudyID: AMBRX1825
ClinicalTrials.gov: NCT04662580

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422